Characterization of endothelin-converting enzyme 1 as a key enzyme in the multienzyme Aβ degradation pathway
Proceedings of the National Academy of Sciences · 04.11.2025 · 122 (44)
DOI: 10.1073/pnas.2507450122 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 27.10.2025. Verfasst von Irem Ulku und 9 weiteren Autor:innen. Beteiligte Einrichtung: Integrated Program in Neuroscience, McGill University, Montreal, QC H3G 0B1, Canada. Hauptthemen laut MEDLINE: Endothelin-Converting Enzymes, Amyloid beta-Peptides, Alzheimer Disease, Aspartic Acid Endopeptidases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Canadian Government | CIHR | Institute of Aging (IA).
Abstract (Originalsprache)
Altered β-amyloid (Aβ) homeostasis is a critical event triggering the shift from healthy aging to Alzheimer disease (AD) through the overproduction and impaired clearance of Aβ peptides. The Aβ-degrading enzymes (ADEs) are a collective group of proteases that normally promote clearance to counteract Aβ-induced neurodegeneration. We previously discovered that the beta-site amyloid precursor protein cleaving enzyme 1 is an atypical ADE that produces the nontoxic fragment Aβ34 by recognizing 40- or 42-residue-long Aβ peptides as substrates in vitro and in vivo. Here, we examined other known ADEs for their potential roles in degrading Aβ34, Aβ40, and Aβ42. By genetic, cellular, and pharmacological approaches, we identified and characterized endothelin-converting enzyme 1 (ECE1) in a human neuroblastoma cell line, human brain vascular pericytes, and primary rat cortical cultures as a major enzyme degrading Aβ34 but not Aβ40 or Aβ42. Notably, we found that ECE1 cleaves Aβ34, an indicator of amyloid clearance, to a unique and unusually stable Aβ20-34 fragment that has the potential to serve as a measurable biomarker. Biocomputational analyses from non-AD controls and individuals with AD pathology showed that the highest messenger ribonucleic acid (mRNA) levels of ECE1 expression were found in pericytes (i.e., cells within the brain microvasculature that are known to produce Aβ34) compared to other cell types. Given Aβ34 is an indicator for prodromal AD, we postulate that our collective findings (i.e., generation of Aβ34 and Aβ20-34 intermediates within the “amyloidolytic” degradation pathway) will generate a set of biomarkers to detect amyloid clearance activity in vivo.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Integrated Program in Neuroscience, McGill University, Montreal, QC H3G 0B1, Canada.
- Department of Pharmacology and Therapeutics, McGill University, Montreal, QC H3G 1Y6, Canada.
- Department of Pediatrics, Centre Hospitalier Universitaire Sainte Justine Research Center, Montreal, QC H3T 1C5, Canada.
- Department of Ophthalmology, Centre Hospitalier Universitaire Sainte Justine Research Center, Montreal, QC H3T 1C5, Canada.
- Department of Pharmacology, Centre Hospitalier Universitaire Sainte Justine Research Center, Montreal, QC H3T 1C5, Canada.
- Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Montreal, QC H3A 2B4, Canada.
ORCID-Profile: Irem Ulku, Mark A Hancock, Hedi Zhou, Gael Cagnone, Jean-Sebastien Joyal, Teddy A J Fisher, Timothy E Kennedy, Filip Liebsch, Gerhard Multhaup
Förderung
- Canadian Government | CIHR | Institute of Aging (IA)
Zitieren
APA
Ulku, I., Ansari, F. E., Hancock, M. A., Zhou, H., Cagnone, G., Joyal, J. S., Fisher, T. A. J., Kennedy, T. E., Liebsch, F., & Multhaup, G. (2025). Characterization of endothelin-converting enzyme 1 as a key enzyme in the multienzyme Aβ degradation pathway. Proceedings of the National Academy of Sciences, 122(44). https://doi.org/10.1073/pnas.2507450122
Vancouver
Ulku I, Ansari FE, Hancock MA, Zhou H, Cagnone G, Joyal JS, et al. Characterization of endothelin-converting enzyme 1 as a key enzyme in the multienzyme Aβ degradation pathway. Proceedings of the National Academy of Sciences. 2025;122(44). doi:10.1073/pnas.2507450122
BibTeX
@article{Ulku2025,
author = {Ulku, Irem and Ansari, Fatima El and Hancock, Mark A and Zhou, Hedi and Cagnone, Gael and Joyal, Jean-Sebastien and Fisher, Teddy A J and Kennedy, Timothy E and Liebsch, Filip and Multhaup, Gerhard},
title = {Characterization of endothelin-converting enzyme 1 as a key enzyme in the multienzyme Aβ degradation pathway},
journal = {Proceedings of the National Academy of Sciences},
year = {2025},
volume = {122},
number = {44},
doi = {10.1073/pnas.2507450122}
}
EUVIMED